Non-Invasive, Early-Stage Liver Fibrosis Diagnostic

Description

This technology is a cutting-edge non-invasive liver fibrosis detection technology, a revolutionary advancement in the early diagnosis of liver fibrosis. Detecting liver fibrosis early is crucial because it helps address and potentially prevent the progression of liver diseases that can lead to more severe conditions such as cirrhosis, liver failure, or liver cancer. This technology interprets data from Doppler ultrasound scans to accurately detect and stage liver fibrosis. Unlike traditional methods, which are often invasive, unreliable, and expensive, our solution offers a safer, more precise alternative for assessing liver health. Late-stage fibrosis is irreversible, but the early stages of liver fibrosis are often asymptomatic. Therefore, there is an urgent need to develop non-invasive liver fibrosis diagnostics for timely medical intervention and management, such as antiviral drugs, immunosuppressants, and lifestyle modifications

Benefits

• Enhanced Accuracy: Provides accurate disease staging from scarring (stage 1) to cirrhosis (stage 4).
• Non-Invasive: Eliminates the need for invasive liver biopsies, minimizing patient discomfort and risk.
• Early Detection: Can identify early-stage fibrosis before symptoms appear, potentially preventing progression to irreversible late-stage fibrosis.

Applications

• Liver fibrosis diagnosis
• Routine screening for high-risk populations

Patent Status

• Issued US Utility Patent US11576609B2 - Noninvasive methods for detecting liver fibrosis - Google Patents
• Issued patent in China, pending in EP.

Publications

PS-188-A novel non-invasive technology for liver fibrosis detection - ScienceDirect

THU-083-Predicting advanced liver fibrosis using deep learning based biopsy image analysis - ScienceDirect

Integrated Study of Liver Fibrosis: Modeling and Clinical Detection